Лисокабтаген маралейцел

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

DB16582

Прочие противоопухолевые препараты

N (не классифицировано FDA)

human culture expanded genetically modified autologous T cells for cell-based gene therapy. CD4+ CD8+ T Cells are derived from isolated blood of the patient and are transduced with non-replicative self-inactivating (SIM) lentiviral vector encoding an FMC63 anti-CD19 single chain variable fragment (scFv) lgG4 hinge region/CD28/CD137 (4- 1BB)/CD3zeta chimeric antigen receptor (CAR) and a truncated form of the human epidermal growth factor receptor (EGFRt) under the control of the elongation factor 1-alpha (EF1-alpha)/R region from the human T cell leukaemia virus 1 (HTLV-1 R) composite promoter. Cells exhibit anti-tumoral activity in patients with CD19- expressing B cell malignancies.

Поделиться этой страницей